Pablo CASTRO PEÑA
@DrCastroPena
Followers
535
Following
2K
Media
41
Statuses
634
Radiation Oncologist - Master in clinical management, medical and care management - University Teacher - Vice_President Latam & Iberic Radiosurgical Society
Córdoba, Argentina
Joined May 2017
Digital oncology is here to stay. Randomized trial of smartphone assisted follow up shows it prevents deterioration of quality of life in head and neck cancer survivors. Stefano Cavalieri at #ESMO25
1
21
39
@DBarreiro4 @Martin_AngelMD @nachogoano @FernanQuirosBA @fedelosco @nataliagandur @sangarciacorre Ahí vamos a estar @oncourologiaarg @EJERCITOARG2014
0
1
2
Todd Scarbrough does it again. This is his as well. Amazing context in the 340B relative to our field. 50% of cancer patients will receive radiation, yet look at that growing gap in favor of drugs.
The @USCBO Congressional Budget Office released "Growth in the 340B Drug Pricing Program" On Sept 2, 2025 https://t.co/5VtXZtyuRG For comparison, I made a graph of "Growth in Radiation Oncology #radonc Spending" over the same time period
0
1
13
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics
https://t.co/UgstAFfvMi
19
75
203
Say hello to single-fraction lung SBRT completed in 1 hour from Sim to Treat. #radonc @WashUMedRadOnc
https://t.co/N1DMA8Q32C
5
20
72
Fundación @UroTeragLATAM La red más grande de educación teragnóstica en habla hispana. Cumplimos 3 años de educar día tras día, de forma multidisciplinaria. 👇👇👇
2
6
9
🚨#ASTRO25 Plenary: Bladder Adj RT (BART): Clinical Outcomes from Phase 3 Multicenter RCT @urotoday @VedangMurthy @RadOncTMC ⚡️n=153; 77 adj RT vs 76 obs ⚡️2-yr LRFS: 87.1% vs 76.0%; HR 0.43, 95% CI 0.20-0.96 ⚡️2-yr DFS: 71.6% vs 58.7%; HR 0.62, 0.36-1.05 ⚡️2-yr Bladder CSS:
1
33
101
PACE-C acute toxicity results: SBRT vs moderate hypofrac #ESTRO24
@alison_tree @ESTRO_RT #radonc #ProstateCancer
0
23
42
Optimizing radiation therapy for #ProstateCancer: Can dose reduction to the pudendal arteries preserve sexual health? Presentation by Sophia Kim-Wang, MD, PhD @UChicago. #ASTRO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/OTDSdTL9zl
@ASTRO_org
1
12
25
💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control &
8
94
226
If you push these efforts too far - shorten the schooling, shorten residency, get rid of the standardized tests, eliminate this and that… Eventually, there is a point at which people will come to believe your job isn’t that special, and could be done by anyone.
💬 Viewpoint: Adoption of a 3-year #MedicalSchool program would reduce costs, modernize education, and alleviate physician shortages. #MedEd
https://t.co/M4CTEudPQs
117
103
943
🇪🇸 A group of investigators from Valencia presents their 10-year experience with single-fraction lung SBRT at #ASTRO25. Their data reports 99% in-field local control with a median f/u time of 5 years. https://t.co/4ZBGA56A9H
1
24
48
RT @_ShankarSiva: 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ do…
0
4
0
🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus
#ASTRO25 #RadOnc
6
61
139
FDA approval today for 177Lu-PSMA-617 in taxane-naive mCRPC https://t.co/KNLoP8gUxy
@urotoday @GACancerCenter
fda.gov
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).
PSMAfore: Ph 3 trial of 177Lu-PSMA-617 in taxane-naive mCRPC #ESMO23 @urotoday 🔹n=468; mFU 7.3 mos 177Lu-PSMA-617 vs ARPI change: 🔹rPFS: HR 0.43, 95%CI 0.33-0.54 🔹ORR: 50.7% vs 14.9%; CR rate: 21.1% vs 2.7% 🔹DOR: 13.6 mos vs 10.1 mos 🔹TT SSE: HR 0.35, 95%CI 0.22-0.57
0
21
42
No crossover No SBRT Are you kidding me?
The MARIPOSA effect 🦋 ‼️Awaited OS data for #Amivantamab + lazertinib vs osimertinib in 1L EGFRm advanced #lungcancer presented by Prof. James Yang at #ELCC25 🎯OS HR 0.75 (95%CI: 0.61-0.92) 🎉> 1 yr mOS advantage 🚫no crossover allowed, ⬆️intracranial activity ⬇️toxicity
0
3
19
🔔📣📢 RADIOSA full paper is finally out! Read our publication now online on @TheLancetOncol! Randomised trial in the metachronous oligomets hormone-sensitive PCa setting reporting improved clinical PFS with the combination of SBRT and a short course of ADT!
11
49
149
Does the ADT destroy micromets or simply delay progression? Luca Valle and I share our thoughts https://t.co/fP2XS6UCWl Again congrats to the authors on this important trial.
thelancet.com
Since the existence of the oligometastatic disease state was posited three decades ago,1 there has been interest in investigating the role of metastasis-directed therapy—largely in the form of...
4
12
28